KEYNOTE-826 Final Analysis
KEYNOTE-826: Final OS Analysis of Pembrolizumab + Chemotherapy vs Placebo + Chemotherapy in Persistent, Recurrent, or Metastatic Cervical Cancer

Released: June 05, 2023

Activity

Progress
1
Course Completed